The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
As of close of business last night, Hologic, Inc’s stock clocked out at $74.97, up 0.23% from its previous closing price of $74.8. In other words, the price has increased by $0.23 from its previous closing price. On the day, 1.03 million shares were traded. HOLX stock price reached its highest trading level at $75.03 during the session, while it also had its lowest trading level at $74.75.
Ratios:
To gain a deeper understanding of HOLX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.59 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.16. For the most recent quarter (mrq), Quick Ratio is recorded 3.06 and its Current Ratio is at 3.75. In the meantime, Its Debt-to-Equity ratio is 0.52 whereas as Long-Term Debt/Eq ratio is at 0.51.
On October 07, 2025, Evercore ISI Upgraded its rating to Outperform which previously was In-line but kept the price unchanged to $78. Argus Upgraded its Hold to Buy on August 18, 2025, while the target price for the stock was maintained at $80.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 20 ’25 when Stamoulis Christiana sold 7,402 shares for $73.07 per share. The transaction valued at 540,864 led to the insider holds 47,336 shares of the business.
Stamoulis Christiana bought 7,402 shares of HOLX for $540,864 on Oct 20 ’25. On Sep 22 ’25, another insider, MACMILLAN STEPHEN P, who serves as the Chairman, President and CEO of the company, sold 138,358 shares for $66.97 each. As a result, the insider received 9,266,118 and left with 1,234,624 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HOLX now has a Market Capitalization of 16711205888 and an Enterprise Value of 17132104704. As of this moment, Hologic,’s Price-to-Earnings (P/E) ratio for their current fiscal year is 30.19, and their Forward P/E ratio for the next fiscal year is 15.00. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.66. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.08 while its Price-to-Book (P/B) ratio in mrq is 3.31. Its current Enterprise Value per Revenue stands at 4.178 whereas that against EBITDA is 12.68.
Stock Price History:
The Beta on a monthly basis for HOLX is 0.70, which has changed by -0.051012635 over the last 52 weeks, in comparison to a change of 0.1326145 over the same period for the S&P500. Over the past 52 weeks, HOLX has reached a high of $80.31, while it has fallen to a 52-week low of $51.90. The 50-Day Moving Average of the stock is 5.14%, while the 200-Day Moving Average is calculated to be 15.32%.
Shares Statistics:
It appears that HOLX traded 3.13M shares on average per day over the past three months and 3545710 shares per day over the past ten days. A total of 222.56M shares are outstanding, with a floating share count of 219.29M. Insiders hold about 1.62% of the company’s shares, while institutions hold 99.43% stake in the company. Shares short for HOLX as of 1763078400 were 3885730 with a Short Ratio of 1.24, compared to 1760486400 on 3501521. Therefore, it implies a Short% of Shares Outstanding of 3885730 and a Short% of Float of 2.3.
Earnings Estimates
. The current rating of Hologic, Inc (HOLX) is the result of assessments by 11.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $1.09, with high estimates of $1.14 and low estimates of $1.05.
Analysts are recommending an EPS of between $4.65 and $4.47 for the fiscal current year, implying an average EPS of $4.56. EPS for the following year is $4.99, with 16.0 analysts recommending between $5.18 and $4.75.
Revenue Estimates
In . The current quarter, 9 analysts expect revenue to total $1.07B. It ranges from a high estimate of $1.09B to a low estimate of $1.05B. As of . The current estimate, Hologic, Inc’s year-ago sales were $1.02BFor the next quarter, 9 analysts are estimating revenue of $1.05B. There is a high estimate of $1.07B for the next quarter, whereas the lowest estimate is $1.04B.
A total of 18 analysts have provided revenue estimates for HOLX’s current fiscal year. The highest revenue estimate was $4.32B, while the lowest revenue estimate was $4.22B, resulting in an average revenue estimate of $4.29B. In the same quarter a year ago, actual revenue was $4.1BBased on 16 analysts’ estimates, the company’s revenue will be $4.52B in the next fiscal year. The high estimate is $4.57B and the low estimate is $4.44B.
